Esta página web usa cookies. ¿Acepta usted el uso de cookies externos? No Saber más x
Encuesta sobre la acondroplasia
Hemos diseñado un cuestionario con el objetivo de conocer la población afectada o cercana a la acondroplasia.
El cuestionario es opcional y anónimo. Los datos obtenidos serán usados para cálculos estadísticos y para poder tener una mejor percepción sobre la historia natural de la acondroplasia.
Por favor, considere e intente responder. Si usted desea responder a las preguntas más tarde, puede presionar el botón en la parte superior "Inscribirse en BA"

Online Survey to Know Current Needs in Rare Bone Conditions

2023-01-20News
As part of the Call to Action project, the European Rare Bone Forum (ERBF) is conducting an online survey to understand the current unmet needs in rare bone conditions, the challenges that exist in research, and potential solutions to overcome these barriers. Participate by February 6, 2023.

FDA approves 1st drug to improve growth in children with achondroplasia

2021-11-23News
On 19 November 2021, the U.S. Food and Drug Administration (FDA) approved Voxzogo (vosoritide), developed by BioMarin, for children with achondroplasia from the age of five, when children still have growth potential as their growth plates (epiphyses) are open.

Listen to the ASBMR 2021 Rare Bone Disease Podcast

2021-10-13News
The ASBMR — The American Society for Bone and Mineral Research — 2021 Annual Meeting Podcasts on Rare Bone Diseases are available for listening.

Quality of life in adults with achondroplasia in the US

2021-09-27News
Study on quality of life and Psychiatric illness in adults with achondroplasia in the US The Kathryn O. and Alan C. Greenberg Center for Skeletal Dysplasias (Hospital for Special Surgery, NY), published a study1 on quality of life (QoL) and diagnosis of psychiatric disorders in a group of adults with achondroplasia in the US. The study consists of the application of 36 questions covering 8 health concepts (see below) and subsequent comparison of the results of thi […]
Para ver esta página web usted necesita de Internet Explorer 8 (o una versión más reciente)
u otro browser.


Muchas gracias.